Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 195-198

  Imrie, Allison ^a   Carr, Andrew ^b   Duncombe, Chris ^b   Finlayson, Robert ^b   Vizzard, Jeanette ^b   Law, Matthew ^b   Kaldor, John ^b   Penny, Ronald ^b   Cooper, David A ^b  

^a Leahi Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CELL COUNT; CODON; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FEVER; GENE MUTATION; GENOTYPE; HEADACHE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PHARYNGITIS; PRIORITY JOURNAL; RASH; SEROCONVERSION; VIRUS TRANSMISSION; WEIGHT REDUCTION;

EID: 0030057987     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.195     Document Type: Article

References (15)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989;243:1731-4.
2. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246: 1155-8.
3. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
4. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immuno-deficiency virus - positive subjects. J Infect Dis 1992;165:105-10.
5. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immuno-deficiency virus. J Acquir Immune Defic Syndr 1990;3:743-6.
6. Loveday C, Kaye S, Tenant-Flowers M, et al. HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
7. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994;169:411-5.
8. Fitzgibbon JE, Gaur S, Frenkel L, Laraque F, Edlin B, Dubin D. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistant mutation. N EngI J Med 1993;329:1835-41.
9. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
10. Kinloch-De Loes S, Hirschell BJ, Hoen B, et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med 1995;333:408-13.
11. Tindall B, Forde S, Goldstein D, Ross MW, Cooper DA. Sexual dysfunction in advanced HIV disease. AIDS Care 1994;6:105-7.
12. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
13. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. Br Med J 1989;299:154-7.
14. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993;328:1163-5.
15. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988;148:945-9.